EPISODE · Jul 21, 2025 · 12 MIN
Compass trials mark a milestone moment for the psychedelics sector
Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.
Embed this episode
NOW PLAYING
Compass trials mark a milestone moment for the psychedelics sector
0:00
12:35
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Pathfinders in Biopharma?
This episode is 12 minutes long.
When was this Pathfinders in Biopharma episode published?
This episode was published on July 21, 2025.
Can I download this Pathfinders in Biopharma episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!